Heart failure with preserved ejection fraction

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 6, 2014, Pages 743-750

  Alsamara, Mershed ^a   Alharethi, Rami ^b  

^a Division of Neurosurgery   (United States)

^b Intermountain Heart Institute   (United States)

Author keywords

Cardiomyopathy; Diastolic dysfunction; HFpEF; Preserved ejection fraction

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CARVEDILOL; CD45 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; IRBESARTAN; IVABRADINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PERINDOPRIL; REACTIVE OXYGEN METABOLITE; RELAXIN; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA;

ANGIOCARDIOGRAPHY; ARTERY COMPLIANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; FOLLOW UP; HEART ATRIUM CONTRACTION; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INDEX; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART MUSCLE OXYGEN CONSUMPTION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MICROVASCULAR ENDOTHELIAL CELL; OBESITY; OXYGEN CONSUMPTION; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL DISEASE BY BODY FUNCTION; PREVALENCE; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; STARLING LAW; ANIMAL; HEART LEFT VENTRICLE FUNCTION; MORTALITY;

ANIMALS; DIURETICS; HEART FAILURE; HUMANS; HYPERTENSION; VENTRICULAR FUNCTION, LEFT;

EID: 84901440717     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.911086     Document Type: Review

References (62)

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16) e147-239
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 Update: A report from the American Heart Association. Circulation 2014;129(3): 399-410
3. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47(5):320-32 (Pubitemid 40884561
4. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289(2):194-202 (Pubitemid 36068707
5. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: Findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007; 153(6):1021-8
6. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355(3):260-9 (Pubitemid 44088349
7. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355(3):251-9 (Pubitemid 44079340
8. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350(19): 1953-9
9. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105(11):1387-93 (Pubitemid 34260433
10. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004;351(11):1097-105
11. Zile MR. Heart failure with preserved ejection fraction: Is this diastolic heart failure?. J Am Coll Cardiol 2003;41(9): 1519-22
12. Borbely A, Van Der Velden J, Papp Z, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005;111(6): 774-81 (Pubitemid 40250638
13. Shah AM, Shah SJ, Anand IS, et al. Cardiac structure and function in heart failure with preserved ejection fraction: Baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2014;7(1):104-15
14. Lewinter MM, Meyer M. Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: If it's not one thing it's another. Circ Heart Fail 2013; 6(6):1112-15
15. Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011;124(23): 2491-501
16. Van Heerebeek L, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113(16):1966-73
17. Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115(7):888-95 (Pubitemid 46294729
18. Zile MR, Desantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011;4(3): 246-56
19. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011;4(1): 44-52
20. Gonzalez A, Lopez B, Querejeta R, Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. J Mol Cell Cardiol 2002; 34(12):1585-93
21. Yamamoto K, Masuyama T, Sakata Y, et al. Roles of renin-Angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000;47(2):274-83 (Pubitemid 30625290
22. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006;114(20):2138-47 (Pubitemid 44747894
23. Phan TT, Shivu GN, Abozguia K, et al. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010;3(1):29-34
24. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62(4):263-71
25. Mckee PA, Castelli WP, Mcnamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971;285(26):1441-6
26. Mcmurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8). 803-69
27. Maisel AS, Mccord J, Nowak RM, et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41(11):2010-17 (Pubitemid 36677124
28. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22(2):107-33
29. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2013;311(5) 507-20
30. Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994;90(6):2761-71
31. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27(19):2338-45 (Pubitemid 44453578
32. Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: Effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010;3(4):477-85
33. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362(9386):777-81 (Pubitemid 37093918
34. Massie BM, Carson PE, Mcmurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359(23):2456-67
35. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6(4): 453-61 (Pubitemid 38746589
36. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3):215-25 (Pubitemid 40222359
37. Van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53(23):2150-8
38. Hernandez AF, Hammill BG, O'connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009;53(2): 184-92
39. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32(6):865-79 (Pubitemid 30663097
40. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-Angiotensin-Aldosterone system. Circulation 1991;83(6):1849-65
41. Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-Treated rats. Endocrinology 2004;145(7):3153-7 (Pubitemid 38829985
42. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011;17(8): 634-42
43. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013;309(8):781-91
44. Redfield MM, Borlaug BA, Lewis GD, et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: Rationale and design. Circ Heart Fail 2012;5(5):653-9
45. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124(2): 164-74
46. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2013; 309(12):1268-77
47. O'connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301(14):1439-50
48. Flynn KE, Pina IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301(14):1451-9
49. Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: A randomized, controlled, single-blind trial. Circ Heart Fail 2010;3(6):659-67
50. Edelmann F, Gelbrich G, Dungen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: Results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58(17): 1780-91
51. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol 2008; 101(3A):3-8
52. Corti R, Burnett JC Jr, Rouleau JL, et al. Vasopeptidase inhibitors: A new therapeutic concept in cardiovascular disease?. Circulation 2001;104(15):1856-62
53. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-Acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50(4):401-14
54. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012; 380(9851):1387-95
55. Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: Review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7(2):75-82
56. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAXAHF): A randomised, placebo-controlled trial. Lancet 2013;381(9860):29-39
57. Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: Results from the RELAX-AHF trial. Eur Heart J 2013. [Epub ahead of print]
58. Kosmala W, Holland DJ, Rojek A, et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: A randomized trial. J Am Coll Cardiol 2013;62(15):1330-8
59. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33(7):1948-55
60. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: Mortality, readmission, and functional decline. J Am Coll Cardiol 2003;41(9):1510-18 (Pubitemid 36543369
61. Henkel DM, Redfield MM, Weston SA, et al. Death in heart failure: A community perspective. Circ Heart Fail 2008;1(2):91-7
62. Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (IPreserve) trial. Circulation 2010;121(12): 1393-405